drugset / Trial / NCT04562311

Chidamide With Immunotherapy for Patients With Locally Advanced or Metastatic Urothelial Carcinoma

NCT04562311

Phase 2 Active not recruiting 45 enrolled Sun Yat-sen University
NaSingle-groupOpen-labelTreatment

Summary

Study of Chidamide Combined With Immunotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Who Had Previously Received Platinum-based Chemotherapy

Timeline

Start
2021-01-01
Primary completion
2024-08-30
Completion
2025-10-30

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Tucidinostat Small molecule 30 mg Oral
Background Tislelizumab Monoclonal antibody 200 mg Intravenous